{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:16:33Z","timestamp":1782274593301,"version":"3.54.5"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000055","name":"National Institute on Deafness and Other Communication Disorders","doi-asserted-by":"publisher","award":["ZIA-DC00008"],"award-info":[{"award-number":["ZIA-DC00008"]}],"id":[{"id":"10.13039\/100000055","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["ZIA BC011513"],"award-info":[{"award-number":["ZIA BC011513"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ebiom.2021.103345","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T23:16:14Z","timestamp":1619651774000},"page":"103345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3589-5054","authenticated-orcid":false,"given":"Ryuhei","family":"Okada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Furusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Vermeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyuki","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Wakiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadanobu","family":"Nagaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Choyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Spanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clint T.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1019-4112","authenticated-orcid":false,"given":"Hisataka","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2021.103345_bib0001","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/nm.2554","article-title":"Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules","volume":"17","author":"Mitsunaga","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2021.103345_bib0002","doi-asserted-by":"crossref","first-page":"10425","DOI":"10.18632\/oncotarget.14425","article-title":"Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity","volume":"8","author":"Ogawa","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ebiom.2021.103345_bib0003","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1021\/acscentsci.8b00565","article-title":"Photoinduced ligand release from a silicon phthalocyanine dye conjugated with monoclonal antibodies: a mechanism of cancer cell cytotoxicity after near-infrared photoimmunotherapy","volume":"4","author":"Sato","year":"2018","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.ebiom.2021.103345_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2009.03992.x","article-title":"Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy","volume":"158","author":"Martinelli","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ebiom.2021.103345_bib0005","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2326-6066.CIR-18-0546","article-title":"Host immunity following near-infrared photoimmunotherapy is enhanced with PD-1 checkpoint blockade to eradicate established antigenic tumors","volume":"7","author":"Nagaya","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ebiom.2021.103345_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2013.12.005","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Nishikawa","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.ebiom.2021.103345_bib0007","doi-asserted-by":"crossref","first-page":"352ra110","DOI":"10.1126\/scitranslmed.aaf6843","article-title":"Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy","volume":"8","author":"Sato","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ebiom.2021.103345_bib0008","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ebiom.2021.103345_bib0009","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","article-title":"Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ebiom.2021.103345_bib0010","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.ebiom.2021.103345_bib0011","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.immuni.2017.03.013","article-title":"Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors","volume":"46","author":"Arce Vargas","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.ebiom.2021.103345_bib0012","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1021\/acs.bioconjchem.9b00547","article-title":"The effect of antibody fragments on CD25 targeted regulatory T cell near-infrared photoimmunotherapy","volume":"30","author":"Okada","year":"2019","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.ebiom.2021.103345_bib0013","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/2326-6066.CIR-19-0517","article-title":"Combined CD44- and CD25-targeted near-infrared photoimmunotherapy selectively kills cancer and regulatory T cells in syngeneic mouse cancer models","volume":"8","author":"Maruoka","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ebiom.2021.103345_bib0014","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/archotol.133.5.495","article-title":"The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium","volume":"133","author":"Hoover","year":"2007","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ebiom.2021.103345_bib0015","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1128\/JVI.02188-07","article-title":"The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth","volume":"82","author":"Spanos","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.ebiom.2021.103345_bib0016","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/hed.21040","article-title":"Preclinical models of HPV+ and HPV- HNSCC in mice: an immune clearance of HPV+ HNSCC","volume":"31","author":"Williams","year":"2009","journal-title":"Head Neck"},{"key":"10.1016\/j.ebiom.2021.103345_bib0017","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1002\/ijc.31240","article-title":"Mouse model of postsurgical primary tumor recurrence and regional lymph node metastasis progression in HPV-related head and neck cancer","volume":"142","author":"Mermod","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ebiom.2021.103345_bib0018","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1172\/JCI27745","article-title":"CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells","volume":"116","author":"Quezada","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ebiom.2021.103345_bib0019","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1600-065X.2011.01007.x","article-title":"Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication","volume":"241","author":"Quezada","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ebiom.2021.103345_bib0020","doi-asserted-by":"crossref","first-page":"8744","DOI":"10.3390\/ijms16048744","article-title":"Addition of interleukin-21 for expansion of T-cells for adoptive immunotherapy of murine melanoma","volume":"16","author":"Zoon","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ebiom.2021.103345_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020270","article-title":"Expansion of T cells with interleukin-21 for adoptive immunotherapy of murine mammary carcinoma","volume":"18","author":"Zoon","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ebiom.2021.103345_bib0022","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrc3559","article-title":"Targeting the ERBB family in cancer: couples therapy","volume":"13","author":"Tebbutt","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ebiom.2021.103345_bib0023","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.molonc.2014.01.006","article-title":"Photoimmunotherapy: comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor","volume":"8","author":"Sato","year":"2014","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ebiom.2021.103345_bib0024","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/nbt1337","article-title":"From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice","volume":"25","author":"Jakobovits","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ebiom.2021.103345_bib0025","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nrd2204","volume":"5","author":"Saltz","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ebiom.2021.103345_bib0026","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.4049\/jimmunol.1200356","article-title":"Crosstalk between human IgG isotypes and murine effector cells","volume":"189","author":"Overdijk","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.ebiom.2021.103345_bib0027","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1073\/pnas.85.13.4852","article-title":"Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity","volume":"85","author":"Steplewski","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ebiom.2021.103345_bib0028","first-page":"1236","article-title":"Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy","volume":"59","author":"Yang","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ebiom.2021.103345_bib0029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1040-8428(00)00134-7","article-title":"Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy","volume":"38","author":"Yang","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ebiom.2021.103345_bib0030","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/eji.200939613","article-title":"In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes","volume":"40","author":"Setiady","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ebiom.2021.103345_bib0031","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/eji.1830260730","article-title":"Administration of anti-interleukin-2 receptor alpha antibody in vivo induces localized autoimmune disease","volume":"26","author":"Taguchi","year":"1996","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ebiom.2021.103345_bib0032","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-11-3687","article-title":"T-regulatory cells: key players in tumor immune escape and angiogenesis","volume":"72","author":"Facciabene","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ebiom.2021.103345_bib0033","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/nri2438","article-title":"Immunotherapy of autoimmunity and cancer: the penalty for success","volume":"8","author":"Caspi","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ebiom.2021.103345_bib0034","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nri3567","article-title":"Human memory T cells: generation, compartmentalization and homeostasis","volume":"14","author":"Farber","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ebiom.2021.103345_bib0035","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.0105-2896.2006.00391.x","article-title":"CD8+ T-cell memory in tumor immunology and immunotherapy","volume":"211","author":"Klebanoff","year":"2006","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ebiom.2021.103345_bib0036","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2021.103345_bib0037","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1038\/cti.2014.16","article-title":"Stem memory T cells (TSCM)-their role in cancer and HIV immunotherapies","volume":"3","author":"Flynn","year":"2014","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.ebiom.2021.103345_bib0038","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1158\/1078-0432.CCR-11-0503","article-title":"Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice","volume":"17","author":"Klebanoff","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ebiom.2021.103345_bib0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113276","article-title":"Photoimmunotherapy of gastric cancer peritoneal carcinomatosis in a mouse model","volume":"9","author":"Sato","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2021.103345_bib0040","doi-asserted-by":"crossref","first-page":"23361","DOI":"10.18632\/oncotarget.8025","article-title":"Near infrared photoimmunotherapy with an anti-mesothelin antibody","volume":"7","author":"Nagaya","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ebiom.2021.103345_bib0041","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.molonc.2016.07.010","article-title":"Near infrared photoimmunotherapy of B-cell lymphoma","volume":"10","author":"Nagaya","year":"2016","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ebiom.2021.103345_bib0042","doi-asserted-by":"crossref","first-page":"8807","DOI":"10.18632\/oncotarget.12410","article-title":"Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody","volume":"8","author":"Nagaya","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ebiom.2021.103345_bib0043","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2967\/jnumed.114.149526","article-title":"Photoimmunotherapy targeting prostate-specific membrane antigen: are antibody fragments as effective as antibodies?","volume":"56","author":"Watanabe","year":"2015","journal-title":"J Nucl Med"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421001389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421001389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:06:05Z","timestamp":1762455965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396421001389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":43,"alternative-id":["S2352396421001389"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103345","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103345"}}